{"schema_version":"secwatch.filing_event.v1","accession":"0001639691-24-000006","form_type":"8-K","ticker":"LIVN","cik":"0001639691","company_name":"LivaNova PLC","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.940871+00:00","generated_at":"2026-06-07T02:21:05.561611+00:00","sec_items":["2.05","2.06","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"LivaNova approves restructuring plan, winds down ACS unit; expects ~$110M impairment in Q4 2023","bullets":["Board approved restructuring to focus on Cardiopulmonary and Neuromodulation; wind down ACS unit by end of 2024.","Pre-tax restructuring charges of $15M-$20M in 2024, including $10M-$12M severance/retention and $5M-$8M other expenses.","Triggering event in Q4 2023 leads to pre-tax non-cash impairment charge up to $110M, primarily for finite-lived intangibles.","Some ACS products transitioned to Cardiopulmonary; LifeSPARC and Hemolung systems to be discontinued by end of 2024.","Company to realign into two reportable segments: Cardiopulmonary and Neuromodulation."],"urls":{"canonical":"https://secwatch.observer/filing/0001639691-24-000006","json":"https://secwatch.observer/filing/0001639691-24-000006.json","markdown":"https://secwatch.observer/filing/0001639691-24-000006.md","text":"https://secwatch.observer/filing/0001639691-24-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1639691/000163969124000006/0001639691-24-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1639691/000163969124000006/livn-20240105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:21:05.561611+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"877ff43a2e9cc8924a42d062ebc4a381a4768921","claim":"LivaNova PLC announced a impairment with charges of up to approximately $110 million affecting Advanced Circulatory Support (\"ACS\") Business Unit.","evidence_excerpt":"the Company expects to incur a pre-tax non-cash impairment charge of up to approximately $110 million in the fourth quarter of 2023","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1639691/000163969124000006/0001639691-24-000006-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"impairment"},{"label":"Charge","value":"up to approximately $110 million"},{"label":"Affected area","value":"Advanced Circulatory Support (\"ACS\") Business Unit"}],"fact_type":"restructuring_charge"},{"claim_id":"edbdf06633601a90b1fdddb5f911deb6d448ddfa","claim":"LivaNova PLC announced a restructuring with charges of $15 million to $20 million affecting Advanced Circulatory Support (\"ACS\") Business Unit.","evidence_excerpt":"the Company expects to incur pre-tax restructuring charges in the range of approximately $15 million to $20 million.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1639691/000163969124000006/0001639691-24-000006-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"$15 million to $20 million"},{"label":"Affected area","value":"Advanced Circulatory Support (\"ACS\") Business Unit"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}